Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | RAD52 | P43351 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 2/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.43 |
| ▸ | TOP2A | P11388 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL5524828 | 0.94 | MEN1 (0.46) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL2052464 | 0.84 | MEN1 (0.57) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL5508099 | 0.82 | MEN1 (0.47) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL5500673 | 0.81 | KMT2A (0.72) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL5502811 | 0.79 | MEN1 (0.47) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL5506961 | 0.77 | MEN1 (0.49) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL18998176 | 0.74 | ALDH1A1 (0.48) | MEN1PKMKMT2AHPGDMAPT | |
| SCHEMBL4788245 | 0.73 | CSF1R (0.56) | MAPTKDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL7540120 | 0.72 | PTPN1 (0.45) | MEN1PKMKMT2AHPGDMAPT | |
| SCHEMBL1959406 | 0.71 | POLB (0.46) | MEN1PKMKMT2APOLBRAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | SIRCAR JAGADISH C | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009487-A1 | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases | LDLR, NPC1L1, CETP | MEN1 4136/4885PKM 1796/4885KMT2A 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.